2019 American Transplant Congress
The Effect Of Tacrolimus Trough Variability On Kidney Transplant Outcomes
*Purpose: High variability in tacrolimus as assessed by tacrolimus coefficient of variability (TCV) in trough levels of kidney transplant recipients (KTRs) has been associated with…2019 American Transplant Congress
Risk of Opportunistic Infection in Kidney Transplant Recipients with Cytomegalovirus Infection and Associated Outcomes
*Purpose: Cytomegalovirus (CMV) infection in kidney transplant recipients has been anecdotally observed with concomitant or subsequent opportunistic infections (OI), but this association has yet to…2019 American Transplant Congress
Use of a CMV Specific T Cell Immunity Assay in Late-Onset CMV Infection
*Purpose: To describe our clinical experience using a CMV Specific Cell Mediated Immunity (CMI) assay in solid organ transplant (SOT) recipients with late-onset CMV, defined…2019 American Transplant Congress
Incidence of Viral Infections in Kidney Transplant Recipients with Alemtuzumab or Rabbit Antithymocyte Globulin Induction
1Tampa General Hospital, Tampa, FL, 2Florida Kidney Physicians, Tampa, FL
*Purpose: Monoclonal antibody therapy causes profound and sustained lymphocyte depletion thus increasing the risk of viral infections. While studies exist evaluating the outcomes of alemtuzumab…2019 American Transplant Congress
CMV Risk Status Remains a Relevant Risk Factor for Long-Term Outcomes
*Purpose: Intensification of immunosuppression using T cell depleting induction has reduced rates of acute cellular rejection after kidney transplantation. Belatacept, a first in class T…2019 American Transplant Congress
Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients
Michigan Medicine, Ann Arbor, MI
*Purpose: Significant controversy surrounds the optimal dose and duration of valganciclovir (VGCV) to prevent CMV in high-risk (D+/R-) liver transplant (LT) recipients. High doses cause…2019 American Transplant Congress
The Natural History and Time to Seroconversion of CMV in the Era of Post-Transplantation Chemoprophylaxis: A Single Center Study
Division of Infectious Diseases, University of Arizona, Tucson, AZ
*Purpose: The current cytomegalovirus (CMV) guidelines in solid organ transplantation recommend chemoprophylaxis (ppx) in post-kidney transplantation recipients. This approach has led to a reduction in…2019 American Transplant Congress
Impact of Cytomegalovirus on the Immune System of Healthy Humans
Emory Transplant Center, Emory University, Atlanta, GA
*Purpose: CMV is a frequent pathogen after transplantation. 2/3 of recipients harbor latent CMV and are at moderate risk. CMV- recipients divide into high or…2019 American Transplant Congress
Letermovir for CMV Treatment in Solid Organ Transplant
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Letermovir (LET), a novel anti-CMV agent, was recently approved for CMV prophylaxis in stem cell transplant recipients and is currently under investigation as a…2019 American Transplant Congress
Pharmacokinetics of Innovative versus Generic Valganciclovir in Kidney Transplant Recipients
*Purpose: In kidney transplant recipients (KTR), cytomegalovirus (CMV) is a common viral infection associated with significant morbidity and mortality. In the absence of prophylaxis, CMV…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 33
- Next Page »